MTOR and prostate cancer: More recently, apoptosis and inhibition of the JAK/STAT3 pathway in cholangiocarcinoma [128], upregulation of miR34a in gastric cancer cells [129], apoptosis and upregulation of Fas signaling in Hep-2 cells [130], apoptosis and interference with PI3K/Akt/mTOR signaling in non-small cell lung cancer [131], cell cycle arrest and apoptosis of liver cancer cell lines [132], ROS generation and intracellular copper mobilization in different cancer cell types [133] and inhibition of cyclin G-associated kinase in PC-3 prostate cancer cells [134] were reported for luteolin.